Keywords: integrilin, cost-effective, says, study, aha, use, cor
Integrilin cost-effective, says study at AHA
Article | 13 November 2001
Use of Cor Therapeutics/Schering-Plough's glycoprotein IIb/IIIainhibitor Integrilin (eptifibatide) in patients undergoing an intracoronary stent procedure is highly cost-effective, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
